Item 1

Call to order

Item 2

Approval of minutes from April 28, 2017 (Vote required)

Item 3

Old business: Report on Health and Human Services Commission decisions on acceptance of the Drug Utilization Review (DUR) Board recommendations from the April 28, 2017, meeting

Item 4

New business:
Public comment on drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):
a. Alzheimer’s agents
b. Antihistamines, minimally sedating
c. Antihypertensives, sympatholytics
d. Antivirals, oral
e. Bile salts
f. Calcium channel blockers
g. Cephalosporins and related antibiotics
h. Fluoroquinolones, oral
i. Glucocorticoids, oral
j. Hypoglycemics, SGLT2
k. Immunosuppressants, oral
l. Iron, oral
m. Leukotriene modifiers
n. NSAIDs
o. Ophthalmic antibiotics
p. Ophthalmic antibiotic-steroid combinations
q. Ophthalmic for allergic conjunctivitis
r. Ophthalmic, anti-inflammatories
s. Ophthalmic, glaucoma agents
t. Otic antibiotics
u. Otic anti-infectives and anesthetics
v. Prenatal vitamins
w. Skeletal muscle relaxants
x. Steroids, topical high
y. Steroids, topical low
z. Steroids, topical medium
aa. Steroids, topical very high
ab. Ulcerative colitis agents

Public comment on new drugs to be reviewed for the Medicaid PDL:
ac. Analgesics, narcotics long/ Arymo ER
ad. Cytokine and CAM antagonists/ Siliq
ae. Glucocorticoids, inhaled/ AirDuo Respiclick
af. Immunomodulators, atopic dermatitis/ Dupixent
ag. Progestational agents/ Makena

Item 5

Therapeutic and clinical drug reviews and updates – Sarah Martinez, Pharm. D., Magellan Medicaid Administration

Items 6 & 7

6. Executive work session
Pursuant to Texas Government Code, Section 531.071, and in accordance with Texas Administrative Code, Title 1, Part 15, Subchapter F, Section
354.1941(c)(2), the DUR Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.

7. Lunch

Item 8

Announcements of drugs recommended for the Medicaid PDL

Item 9

Retrospective DUR: Luke Boehmer, Pharm. D., Conduent, LLC
a. Report on recent retrospective DUR interventions sent:
i. Naloxone for opioid-related overdose
ii. Diabetes disease management 2017

b. Report on recent retrospective DUR interventions outcome:
i. Diabetes disease management 2016
ii. Multiple drug therapy regimen review (Polypharmacy) 2016

c. Retrospective DUR proposals: (Vote required)
i. Opioid use during pregnancy
ii. Multiple drug therapy regimen review (Polypharmacy) 2017
iii. Stroke prevention 2017

Item 10

Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (Vote required)
a. Diclofenac 3% Gel, Diclofenac 1.5% and 2% Topical Solution
b. Dupixent (Dupilumab)
c. Emflaza (Deflazacort)
d. Nuplazid (Pimavanserin)

Item 11

Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy
(Vote required)
a. Acetylcholinesterase Inhibitors
b. Oral/Rectal Benzodiazepines
c. Exogenous Insulin Products
d. Low-Molecular-Weight Heparins
e. Memantine (Namenda)
f. Rifaximin (Xifaxan)

Items 12 & 13

12. Adjourn

13. Next meeting date: Nov. 3, 2017